Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Chemosensitivity Study of Colorectal Cancer Using Xenografts of Patient-Derived Tumor-Initiating Cells.

Molecular cancer therapeutics - 1 Oct 2018

Maekawa Hisatsugu, Miyoshi Hiroyuki, Yamaura Tadayoshi, Itatani Yoshiro, Kawada Kenji, Sakai Yoshiharu, Taketo M Mark

Abstract excerpt

Current genomic and gene expression analyses provide versatile tools to improve cancer chemotherapy. However, it is still difficult to predict whether each patient responds to a particular regimen or not. To predict chemosensitivity in each patient with colorectal cancer, we developed an evaluation method using the primary tumor-initiating cells (TIC, aka cancer stem cells) xenografted in nude mice subcutaneously...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Drug Resistance, Neoplasm

Share to Neoplastic Stem Cells

Share to Positron-Emission Tomography

Share to Tomography, X-Ray Computed

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 29970483
DOI: 10.1158/1535-7163.MCT-18-0128

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Chemosensitivity Study of Colorectal Cancer Using Xenografts of Patient-Derived Tumor-Initiating Cells.PMID 29970483Read ↗

A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of Patient-Derived Tumor Xenograft (PDTX)Semantic proximity Read ↗

Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal CancerSemantic proximity Read ↗

Modeling rectal cancer to advance neoadjuvant precision therapy.Semantic proximity Read ↗

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.Semantic proximity Read ↗

In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer.Semantic proximity Read ↗

PDXGEM: Patient-Derived Tumor Xenograft based Gene Expression Model for Predicting Clinical Response to Anticancer Therapy in Cancer PatientsSemantic proximity Read ↗

Recent applications of chemosensitivity tests for colorectal cancer treatment.Semantic proximity Read ↗

Establishment and its Utility of a Patient-Derived Cell Xenografts (PDCX) Model with Cryopreserved Cancer Cells from Human TumorSemantic proximity Read ↗

Modeling adaptive drug resistance of colorectal cancer and therapeutic interventions with tumor spheroidsSemantic proximity Read ↗

Establishment of a hepatocellular carcinoma patient‐derived xenograft platform and its application in biomarker identificationSemantic proximity Read ↗

Retaining cell–cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancerSemantic proximity Read ↗

A fast and efficient model for real-time anti-tumor drug efficacy test in the clinical setting based on patient-derived tumor xenograftSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.